Risk for cytomegalovirus disease in patients receiving polymerase chain reaction–based preemptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modality
Open Access
- 1 April 2001
- journal article
- Published by American Society of Hematology in Blood
- Vol. 97 (7) , 2183-2185
- https://doi.org/10.1182/blood.v97.7.2183
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infectionBone Marrow Transplantation, 2000
- Increased Incidence of Cytomegalovirus Disease After Autologous CD34-Selected Peripheral Blood Stem Cell TransplantationBlood, 1999
- Late Cytomegalovirus Pneumonia in Adult Allogeneic Blood and Marrow Transplant RecipientsClinical Infectious Diseases, 1999
- Comparison of Immune Reconstitution After Unrelated and Related T-Cell–Depleted Bone Marrow Transplantation: Effect of Patient Age and Donor Leukocyte InfusionsBlood, 1999
- Cytomegalovirus Monitoring by Polymerase Chain Reaction of Whole Blood Samples from Patients Undergoing Autologous Bone Marrow or Peripheral Blood Progenitor Cell TransplantationThe Journal of Infectious Diseases, 1997
- Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV diseaseBone Marrow Transplantation, 1997
- Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantationBlood, 1995
- Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxisBlood, 1994